Recorded Presentation from the NCCN Pharmacy Updates: Infection Concerns with Emerging Immune-targeted Treatments in Immunocompromised Patients with Cancer
Although the toxicity profiles of the newer molecularly targeted drugs are less focused on blood cells than those of traditional cytotoxic therapies, there are still infectious risks; safety and efficacy can only be guaranteed by multidisciplinary teams that have therapeutic expertise in the pharmacology of oral anti-cancer therapy.
Category
  • Supportive Care Topics
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation